What is CMS-0062-P, and what does it mean for healthcare interoperability and drug prior authorization in the US?
In the third episode of our Interoperability Masterclass, interoperability expert and solution architect Yanick Gaudet explains how the proposed CMS-0062-P rule builds on CMS-0057-F and what it could mean for payers, providers, PBMs and other healthcare stakeholders.
The episode breaks down the role of FHIR, HL7 Da Vinci implementation guides and NCPDP standards in electronic drug prior authorization, including why medical-benefit and pharmacy-benefit workflows need to work together and why technical compliance alone does not create true interoperability.
Yanick also explains what organizations should assess now to build the right interoperability roadmap.
Watch the episode to learn:
- What CMS-0062-P proposes
- How it builds on CMS-0057-F
- The role of FHIR and HL7 Da Vinci in prior authorization
- Where NCPDP fits into drug workflows
- Why interoperability requires more than APIs
- What healthcare organizations should do next
